What is Sonic Incytes Medical?
Sonic Incytes Medical is a health technology company founded in 2017 and headquartered in Vancouver, British Columbia, Canada. The company is dedicated to creating accessible and affordable diagnostic solutions to improve patient care, with a specific focus on addressing the rise of chronic liver disease. Its flagship product, Velacur, is a point-of-care ultrasound solution designed to quantify chronic liver disease with diagnostic accuracy comparable to MRI, aiming to redefine the standard of care for routine assessment and improved management of liver health.
How much funding has Sonic Incytes Medical raised?
Sonic Incytes Medical has raised a total of $10.1M across 2 funding rounds:
Angel/Seed
$2.8M
Series A
$7.3M
Angel/Seed (2020): $2.8M with participation from Tmfox Venture Partners, World Changing Ventures, Think Top Investments, UBC Seed Fund, Small World Group, E Fund Management, Genome British Columbia and Genome Canada, and Sunhope Capital
Series A (2021): $7.3M led by Gaingels, Wavemaker Three-Sixty Health, Mint Venture Partners, INP Capital, Nimbus Synergies, Consortium Medteq, and NICOLA WEALTH MANAGEMENT
Key Investors in Sonic Incytes Medical
Gaingels
Gaingels is a leading investment syndicate supporting the LGBTQ community and allies, investing in high-growth companies across various sectors, including healthcare, with a focus on inclusive teams.
Wavemaker Three-Sixty Health
Wavemaker Three-Sixty Health is a venture capital fund exclusively focused on early-stage healthcare startups, aiming to improve patient experiences and lower costs through transformative healthcare innovations.
Mint Venture Partners
Mint Venture Partners is a global venture platform specializing in creating, building, and investing in biotech and healthcare startups, offering support for business development and investment.
What's next for Sonic Incytes Medical?
The substantial enterprise-level funding and recent strategic investment indicate that Sonic Incytes Medical is poised for significant scaling and market penetration. This capital infusion will likely be directed towards further research and development, expanding manufacturing capabilities, and broadening commercialization efforts for its Velacur system. The company's focus on a critical unmet need in chronic liver disease management positions it for substantial growth and impact within the global healthcare technology sector. Future strategic partnerships and further funding rounds may be anticipated as the company progresses through its growth trajectory.
See full Sonic Incytes Medical company page
